Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco WilderHill Clean Energy ETF (PBW) vs Sana Biotechnology Inc (SANA) Price & Performance

Invesco WilderHill Clean Energy ETFTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Invesco WilderHill Clean Energy ETF vs Sana Biotechnology Inc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $31.54, while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

PBWSANA
Sector
Sector/ThematicHealth
52-Week High
$46.99$5.92
52-Week Low
$24.75$2.68
Market Cap
$1.03B
Enterprise Value
$946.04M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco WilderHill Clean Energy ETF

PBW (Invesco WilderHill Clean Energy ETF) trades at $32.38, up 1.86% today, but technical indicators show a bearish trend with moving averages signaling selling pressure. The ETF's unique selection criteria focusing on ecological factors over financial metrics creates an undiversified portfolio that has underperformed broader markets. Recent market volatility from geopolitical tensions and tech sector sell-offs has impacted clean energy ETFs despite long-term growth catalysts.

The clean energy sector faces near-term headwinds from market volatility, though long-term prospects remain supported by global energy security concerns and substantial international investment. PBW's performance remains tied to clean energy adoption trends and policy developments, with current technical weakness suggesting cautious near-term positioning.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco WilderHill Clean Energy ETF

PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.

Read more on PBW

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA